A Phase II Study to Evaluate the Efficacy and Safety of Docetaxel-PM in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 04 May 2017
At a glance
- Drugs Docetaxel (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Samyang Biopharmaceuticals Corporation
- 27 Apr 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2020.
- 27 Apr 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2020.
- 08 Jan 2016 New trial record